Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin

A. L. Khandoga, Y. Fujiwara, P. Goyal, D. Pandey, R. Tsukahara, A. Bolen, H. Guo, N. Wilke, J. Liu, W. J. Valentine, G. G. Durgam, Duane Miller, G. Jiang, G. D. Prestwich, Gabor Tigyi, W. Siess

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Lysophosphatidic acid (LPA), a component of mildly-oxidized LDL and the lipid rich core of atherosclerotic plaques, elicits platelet activation. LPA is the ligand of G protein-coupled receptors (GPCR) of the EDG family (LPA1-3) and the newly identified LPA4-7 subcluster. LPA4, LPA5 and LPA7 increase cellular cAMP levels that would induce platelet inhibition rather than activation. In the present study we quantified the mRNA levels of the LPA1-7 GPCR in human platelets and found a rank order LPA4 = LPA5 > LPA7 > LPA6 = LPA2 ≫ LPA1 > LPA3. We examined platelet shape change using a panel of LPA receptor subtype-selective agonists and antagonists and compared them with their pharmacological profiles obtained in heterologous LPA1-5 receptor expression systems. Responses to different natural acyl and alkyl species of LPA, and octyl phosphatidic acid analogs, alpha-substituted phosphonate analogs, N-palmitoyl-tyrosine phosphoric acid, N-palmitoyl-serine phosphoric acid were tested. All of these compounds elicited platelet activation and also inhibited LPA-induced platelet shape change after pre-incubation, suggesting that receptor desensitization is likely responsible for the inhibition of this response. Fatty acid free albumin (10 μM) lacking platelet activity completely inhibited platelet shape change induced by LPA with an IC50 of 1.1 μM but had no effect on the activation of LPA1,2,3,&5 expressed in endogenously non-LPA-responsive RH7777 cells. However, albumin reduced LPA4 activation and shifted the dose-response curve to the right. LPA5 transiently expressed in RH7777 cells showed preference to alkyl-LPA over acyl-LPA that is similar to that in platelets. LPA did not increase cAMP levels in platelets. In conclusion, our results with the pharmacological compounds and albumin demonstrate that LPA does not induce platelet shape change simply through activation of LPA1-5, and the receptor(s) mediating LPA-induced platelet activation remains elusive.

Original languageEnglish (US)
Pages (from-to)415-427
Number of pages13
JournalPlatelets
Volume19
Issue number6
DOIs
StatePublished - Sep 1 2008

Fingerprint

Lysophosphatidic Acid Receptors
Albumins
Blood Platelets
Platelet Activation
lysophosphatidic acid
Pharmacology
Organophosphonates
Phosphatidic Acids
Atherosclerotic Plaques
G-Protein-Coupled Receptors
Nonesterified Fatty Acids
Inhibitory Concentration 50

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Khandoga, A. L., Fujiwara, Y., Goyal, P., Pandey, D., Tsukahara, R., Bolen, A., ... Siess, W. (2008). Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin. Platelets, 19(6), 415-427. https://doi.org/10.1080/09537100802220468

Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin. / Khandoga, A. L.; Fujiwara, Y.; Goyal, P.; Pandey, D.; Tsukahara, R.; Bolen, A.; Guo, H.; Wilke, N.; Liu, J.; Valentine, W. J.; Durgam, G. G.; Miller, Duane; Jiang, G.; Prestwich, G. D.; Tigyi, Gabor; Siess, W.

In: Platelets, Vol. 19, No. 6, 01.09.2008, p. 415-427.

Research output: Contribution to journalArticle

Khandoga, AL, Fujiwara, Y, Goyal, P, Pandey, D, Tsukahara, R, Bolen, A, Guo, H, Wilke, N, Liu, J, Valentine, WJ, Durgam, GG, Miller, D, Jiang, G, Prestwich, GD, Tigyi, G & Siess, W 2008, 'Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin', Platelets, vol. 19, no. 6, pp. 415-427. https://doi.org/10.1080/09537100802220468
Khandoga, A. L. ; Fujiwara, Y. ; Goyal, P. ; Pandey, D. ; Tsukahara, R. ; Bolen, A. ; Guo, H. ; Wilke, N. ; Liu, J. ; Valentine, W. J. ; Durgam, G. G. ; Miller, Duane ; Jiang, G. ; Prestwich, G. D. ; Tigyi, Gabor ; Siess, W. / Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin. In: Platelets. 2008 ; Vol. 19, No. 6. pp. 415-427.
@article{5f36ddd70fdc4957971532f8cb59c386,
title = "Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin",
abstract = "Lysophosphatidic acid (LPA), a component of mildly-oxidized LDL and the lipid rich core of atherosclerotic plaques, elicits platelet activation. LPA is the ligand of G protein-coupled receptors (GPCR) of the EDG family (LPA1-3) and the newly identified LPA4-7 subcluster. LPA4, LPA5 and LPA7 increase cellular cAMP levels that would induce platelet inhibition rather than activation. In the present study we quantified the mRNA levels of the LPA1-7 GPCR in human platelets and found a rank order LPA4 = LPA5 > LPA7 > LPA6 = LPA2 ≫ LPA1 > LPA3. We examined platelet shape change using a panel of LPA receptor subtype-selective agonists and antagonists and compared them with their pharmacological profiles obtained in heterologous LPA1-5 receptor expression systems. Responses to different natural acyl and alkyl species of LPA, and octyl phosphatidic acid analogs, alpha-substituted phosphonate analogs, N-palmitoyl-tyrosine phosphoric acid, N-palmitoyl-serine phosphoric acid were tested. All of these compounds elicited platelet activation and also inhibited LPA-induced platelet shape change after pre-incubation, suggesting that receptor desensitization is likely responsible for the inhibition of this response. Fatty acid free albumin (10 μM) lacking platelet activity completely inhibited platelet shape change induced by LPA with an IC50 of 1.1 μM but had no effect on the activation of LPA1,2,3,&5 expressed in endogenously non-LPA-responsive RH7777 cells. However, albumin reduced LPA4 activation and shifted the dose-response curve to the right. LPA5 transiently expressed in RH7777 cells showed preference to alkyl-LPA over acyl-LPA that is similar to that in platelets. LPA did not increase cAMP levels in platelets. In conclusion, our results with the pharmacological compounds and albumin demonstrate that LPA does not induce platelet shape change simply through activation of LPA1-5, and the receptor(s) mediating LPA-induced platelet activation remains elusive.",
author = "Khandoga, {A. L.} and Y. Fujiwara and P. Goyal and D. Pandey and R. Tsukahara and A. Bolen and H. Guo and N. Wilke and J. Liu and Valentine, {W. J.} and Durgam, {G. G.} and Duane Miller and G. Jiang and Prestwich, {G. D.} and Gabor Tigyi and W. Siess",
year = "2008",
month = "9",
day = "1",
doi = "10.1080/09537100802220468",
language = "English (US)",
volume = "19",
pages = "415--427",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Lysophosphatidic acid-induced platelet shape change revealed through LPA1-5 receptor-selective probes and albumin

AU - Khandoga, A. L.

AU - Fujiwara, Y.

AU - Goyal, P.

AU - Pandey, D.

AU - Tsukahara, R.

AU - Bolen, A.

AU - Guo, H.

AU - Wilke, N.

AU - Liu, J.

AU - Valentine, W. J.

AU - Durgam, G. G.

AU - Miller, Duane

AU - Jiang, G.

AU - Prestwich, G. D.

AU - Tigyi, Gabor

AU - Siess, W.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Lysophosphatidic acid (LPA), a component of mildly-oxidized LDL and the lipid rich core of atherosclerotic plaques, elicits platelet activation. LPA is the ligand of G protein-coupled receptors (GPCR) of the EDG family (LPA1-3) and the newly identified LPA4-7 subcluster. LPA4, LPA5 and LPA7 increase cellular cAMP levels that would induce platelet inhibition rather than activation. In the present study we quantified the mRNA levels of the LPA1-7 GPCR in human platelets and found a rank order LPA4 = LPA5 > LPA7 > LPA6 = LPA2 ≫ LPA1 > LPA3. We examined platelet shape change using a panel of LPA receptor subtype-selective agonists and antagonists and compared them with their pharmacological profiles obtained in heterologous LPA1-5 receptor expression systems. Responses to different natural acyl and alkyl species of LPA, and octyl phosphatidic acid analogs, alpha-substituted phosphonate analogs, N-palmitoyl-tyrosine phosphoric acid, N-palmitoyl-serine phosphoric acid were tested. All of these compounds elicited platelet activation and also inhibited LPA-induced platelet shape change after pre-incubation, suggesting that receptor desensitization is likely responsible for the inhibition of this response. Fatty acid free albumin (10 μM) lacking platelet activity completely inhibited platelet shape change induced by LPA with an IC50 of 1.1 μM but had no effect on the activation of LPA1,2,3,&5 expressed in endogenously non-LPA-responsive RH7777 cells. However, albumin reduced LPA4 activation and shifted the dose-response curve to the right. LPA5 transiently expressed in RH7777 cells showed preference to alkyl-LPA over acyl-LPA that is similar to that in platelets. LPA did not increase cAMP levels in platelets. In conclusion, our results with the pharmacological compounds and albumin demonstrate that LPA does not induce platelet shape change simply through activation of LPA1-5, and the receptor(s) mediating LPA-induced platelet activation remains elusive.

AB - Lysophosphatidic acid (LPA), a component of mildly-oxidized LDL and the lipid rich core of atherosclerotic plaques, elicits platelet activation. LPA is the ligand of G protein-coupled receptors (GPCR) of the EDG family (LPA1-3) and the newly identified LPA4-7 subcluster. LPA4, LPA5 and LPA7 increase cellular cAMP levels that would induce platelet inhibition rather than activation. In the present study we quantified the mRNA levels of the LPA1-7 GPCR in human platelets and found a rank order LPA4 = LPA5 > LPA7 > LPA6 = LPA2 ≫ LPA1 > LPA3. We examined platelet shape change using a panel of LPA receptor subtype-selective agonists and antagonists and compared them with their pharmacological profiles obtained in heterologous LPA1-5 receptor expression systems. Responses to different natural acyl and alkyl species of LPA, and octyl phosphatidic acid analogs, alpha-substituted phosphonate analogs, N-palmitoyl-tyrosine phosphoric acid, N-palmitoyl-serine phosphoric acid were tested. All of these compounds elicited platelet activation and also inhibited LPA-induced platelet shape change after pre-incubation, suggesting that receptor desensitization is likely responsible for the inhibition of this response. Fatty acid free albumin (10 μM) lacking platelet activity completely inhibited platelet shape change induced by LPA with an IC50 of 1.1 μM but had no effect on the activation of LPA1,2,3,&5 expressed in endogenously non-LPA-responsive RH7777 cells. However, albumin reduced LPA4 activation and shifted the dose-response curve to the right. LPA5 transiently expressed in RH7777 cells showed preference to alkyl-LPA over acyl-LPA that is similar to that in platelets. LPA did not increase cAMP levels in platelets. In conclusion, our results with the pharmacological compounds and albumin demonstrate that LPA does not induce platelet shape change simply through activation of LPA1-5, and the receptor(s) mediating LPA-induced platelet activation remains elusive.

UR - http://www.scopus.com/inward/record.url?scp=54249134426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249134426&partnerID=8YFLogxK

U2 - 10.1080/09537100802220468

DO - 10.1080/09537100802220468

M3 - Article

VL - 19

SP - 415

EP - 427

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 6

ER -